The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.

Onapgo (Supernus), a solution for continuous subcutaneous infusion containing the dopamine agonist apomorphine, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Subcutaneously injected apomorphine (Apokyn, and generics) has been available for intermittent use for years. Vyalev, a foscarbidopa/foslevodopa solution for subcutaneous infusion, was approved in 2024 for the same indication.

Vyalev (Abbvie), a solution for continuous subcutaneous infusion containing the prodrugs foscarbidopa and foslevodopa, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Vyalev is the first subcutaneously administered product to become available in the US for treatment of PD symptoms. Duopa, a carbidopa/levodopa enteral suspension infused via a nasojejunal tube or percutaneous gastrostomy, was approved in for the same indication 2015.